These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

263 related items for PubMed ID: 20926996

  • 1. Population pharmacokinetic analysis of mycophenolic acid coadministered with either tasocitinib (CP-690,550) or tacrolimus in adult renal allograft recipients.
    Lamba M, Tafti B, Melcher M, Chan G, Krishnaswami S, Busque S.
    Ther Drug Monit; 2010 Dec; 32(6):778-81. PubMed ID: 20926996
    [Abstract] [Full Text] [Related]

  • 2. Population Pharmacokinetic Analysis of Immediate-Release Oral Tacrolimus Co-administered with Mycophenolate Mofetil in Corticosteroid-Free Adult Kidney Transplant Recipients.
    Rong Y, Mayo P, Ensom MHH, Kiang TKL.
    Eur J Drug Metab Pharmacokinet; 2019 Jun; 44(3):409-422. PubMed ID: 30377942
    [Abstract] [Full Text] [Related]

  • 3. Differences in clearance of mycophenolic acid among renal transplant recipients, hematopoietic stem cell transplant recipients, and patients with autoimmune disease.
    de Winter BC, Mathot RA, Sombogaard F, Neumann I, van Hest RM, Doorduijn JK, van Gelder T.
    Ther Drug Monit; 2010 Oct; 32(5):606-14. PubMed ID: 20720518
    [Abstract] [Full Text] [Related]

  • 4. Population pharmacokinetics of mycophenolic acid in renal transplant recipients.
    van Hest RM, van Gelder T, Vulto AG, Mathot RA.
    Clin Pharmacokinet; 2005 Oct; 44(10):1083-96. PubMed ID: 16176120
    [Abstract] [Full Text] [Related]

  • 5. Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients.
    Kuypers DR, Claes K, Evenepoel P, Maes B, Vanrenterghem Y.
    Clin Pharmacol Ther; 2004 May; 75(5):434-47. PubMed ID: 15116056
    [Abstract] [Full Text] [Related]

  • 6. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
    Pawinski T, Durlik M, Szlaska I, Urbanowicz A, Majchrnak J, Gralak B.
    J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics, efficacy, and safety of mycophenolate mofetil in combination with standard-dose or reduced-dose tacrolimus in liver transplant recipients.
    Nashan B, Saliba F, Durand F, Barcéna R, Herrero JI, Mentha G, Neuhaus P, Bowles M, Patch D, Bernardos A, Klempnauer J, Bouw R, Ives J, Mamelok R, McKay D, Truman M, Marotta P.
    Liver Transpl; 2009 Feb; 15(2):136-47. PubMed ID: 19177449
    [Abstract] [Full Text] [Related]

  • 8. Population pharmacokinetics analysis of mycophenolic acid in adult kidney transplant patients with chronic graft dysfunction.
    Guillet BA, Simon NS, Purgus R, Botta C, Morange S, Berland Y, Pisano PS.
    Ther Drug Monit; 2010 Aug; 32(4):427-32. PubMed ID: 20592648
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics of enteric-coated mycophenolate sodium: comparative study in patients with autoimmune disease and renal allograft.
    Neumann I, Fuhrmann H, Kanzler M, Fang IF, Jaeger A, Graf H, Bayer P, Kovarik J.
    Expert Opin Pharmacother; 2008 Apr; 9(6):879-86. PubMed ID: 18377332
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics of mycophenolic acid and its phenolic-glucuronide and ACYl glucuronide metabolites in stable thoracic transplant recipients.
    Ting LS, Partovi N, Levy RD, Riggs KW, Ensom MH.
    Ther Drug Monit; 2008 Jun; 30(3):282-91. PubMed ID: 18520599
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients.
    de Winter BC, van Gelder T, Sombogaard F, Shaw LM, van Hest RM, Mathot RA.
    J Pharmacokinet Pharmacodyn; 2009 Dec; 36(6):541-64. PubMed ID: 19904584
    [Abstract] [Full Text] [Related]

  • 13. Concentrations of mycophenolic acid and glucuronide metabolites under concomitant therapy with cyclosporine or tacrolimus.
    Patel CG, Harmon M, Gohh RY, Akhlaghi F.
    Ther Drug Monit; 2007 Feb; 29(1):87-95. PubMed ID: 17304155
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The role of proton pump inhibitors on early mycophenolic acid exposure in kidney transplantation: evidence from the CLEAR study.
    Kiberd BA, Wrobel M, Dandavino R, Keown P, Gourishankar S.
    Ther Drug Monit; 2011 Feb; 33(1):120-3. PubMed ID: 21192310
    [Abstract] [Full Text] [Related]

  • 16. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients.
    Kuypers DR, Claes K, Evenepoel P, Maes B, Coosemans W, Pirenne J, Vanrenterghem Y.
    Clin Pharmacokinet; 2004 Feb; 43(11):741-62. PubMed ID: 15301578
    [Abstract] [Full Text] [Related]

  • 17. Time-dependent clearance of mycophenolic acid in renal transplant recipients.
    van Hest RM, van Gelder T, Bouw R, Goggin T, Gordon R, Mamelok RD, Mathot RA.
    Br J Clin Pharmacol; 2007 Jun; 63(6):741-52. PubMed ID: 17214827
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Time to reach tacrolimus maximum blood concentration,mean residence time, and acute renal allograft rejection: an open-label, prospective, pharmacokinetic study in adult recipients.
    Kuypers DR, Vanrenterghem Y.
    Clin Ther; 2004 Nov; 26(11):1834-44. PubMed ID: 15639695
    [Abstract] [Full Text] [Related]

  • 20. Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil.
    Kuypers DR, Vanrenterghem Y, Squifflet JP, Mourad M, Abramowicz D, Oellerich M, Armstrong V, Shipkova M, Daems J.
    Ther Drug Monit; 2003 Oct; 25(5):609-22. PubMed ID: 14508385
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.